Clinical Trial Update: A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement [Phase 2]

View source ↗

Summary

A multicenter, randomized Phase 2 trial evaluating ARX-F01 (sublingual sufentanil) for postoperative pain after elective unilateral total knee replacement; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Pain

Drugs mentioned

• ARX-F01 (sufentanil)

Snippet

Sponsor: Talphera, Inc | Conditions: Post Operative Pain | Phase 2 | Status: COMPLETED | Results posted: 2014-02-17